Dadaglio Gilles, Morel Sandra, Bauche Cécile, Moukrim Zhora, Lemonnier François A, Van Den Eynde Benoît J, Ladant Daniel, Leclerc Claude
Unit of Biology of Immune Regulations, INSERM E352, Institut Pasteur, 75724 Paris Cedex 15, France.
Int Immunol. 2003 Dec;15(12):1423-30. doi: 10.1093/intimm/dxg144.
The adenylate cyclase (CyaA) of Bordetella pertussis is able to deliver CD8(+) T cell epitopes into the cytosol of CD11b(+) dendritic cells (DC) following its specific interaction with the alpha(M)beta(2) integrin (CD11b/CD18). This delivery results in intracellular processing and presentation by MHC class I molecules of the CD8(+) T cell epitopes inserted into CyaA. Indeed, we previously showed that CyaA toxins carrying a single cytotoxic T lymphocyte (CTL) epitope can induce efficient protective and therapeutic antitumor immunity in mice. With a view to elaborating cancer immunotherapy in humans using CyaA, we constructed two recombinant CyaA carrying HLA0201-restricted melanoma epitopes. Here we show that these recombinant CyaA induce strong anti-melanoma CTL responses in HLA0201 transgenic mice, even after a single i.v. immunization without adjuvant. These responses are long lasting, since they were also detected 5 months after the last injection. Finally, human DC treated with the recombinant CyaA were shown to process and present efficiently the melanoma epitopes to human CTL clones. Altogether, our results demonstrate that tumoral epitopes inserted into CyaA are efficiently processed and presented in association with human MHC molecules. These observations suggest that CyaA is capable of activating antitumoral CTL in humans and highlight the potential of CyaA for use in cancer immunotherapy.
百日咳博德特氏菌的腺苷酸环化酶(CyaA)在与α(M)β2整合素(CD11b/CD18)特异性相互作用后,能够将CD8+ T细胞表位递送至CD11b+树突状细胞(DC)的胞质溶胶中。这种递送导致插入CyaA的CD8+ T细胞表位在MHC I类分子的作用下进行细胞内加工和呈递。事实上,我们之前表明携带单个细胞毒性T淋巴细胞(CTL)表位的CyaA毒素能够在小鼠中诱导高效的保护性和治疗性抗肿瘤免疫。为了利用CyaA开展人类癌症免疫疗法,我们构建了两种携带HLA0201限制性黑色素瘤表位的重组CyaA。在此我们表明,这些重组CyaA即使在无佐剂单次静脉注射免疫后,也能在HLA0201转基因小鼠中诱导强烈的抗黑色素瘤CTL反应。这些反应具有持久性,因为在最后一次注射后5个月仍能检测到。最后,用重组CyaA处理的人DC被证明能够有效地将黑色素瘤表位加工并呈递给人CTL克隆。总之,我们的结果表明,插入CyaA的肿瘤表位能够与人类MHC分子结合进行高效加工和呈递。这些观察结果表明CyaA能够在人类中激活抗肿瘤CTL,并突出了CyaA在癌症免疫疗法中的应用潜力。